SAN DIEGO, CA, Mar. 19, 2025 /Circular Genomics Communications/ —Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced the appointment of Phyllis Ferrell, MBA, DrPH, to its Scientific Advisory Board (SAB). With deep expertise in Alzheimer’s disease (AD), dementia care, and global health initiatives, Phyllis will provide strategic insights to support Circular Genomics’ mission of improving the diagnosis and treatment of psychiatric and neurological disorders.

“We are thrilled to welcome Dr. Ferrell to our Scientific Advisory Board,” said Nikolaos Mellios, MD, PhD, Chief Scientific Officer of Circular Genomics. “Her deep experience in AD research will be invaluable as we continue to explore innovative solutions for early and accurate diagnosis and treatment of this devastating disease that affects millions of people across the world. As we investigate the potential of circRNAs as blood biomarkers for AD, Dr. Ferrell’s expertise will play a crucial role in helping us shape our scientific and clinical strategy with the goal of revolutionizing care for patients.”

Read the full article on circulargenomics.com